1. clinical diagnosis of critically serious lung involvement associated with sars-cov-2 virus infection according to the criteria of the national health commission of china, that is, patients who meet any of the following criteria: 1. respiratory failure requiring invasive mechanical ventilation; or 2. shock; or 3. combination with failure of another organ; need for icu admission for monitoring / treatment. 2. patients who are expected to develop rapidly fatal disease within 72 hours of enrollment. 3. inability to maintain a mean arterial pressure \> 50 mmhg before selection despite the presence of vasopressors and intravenous fluids. 4. patients requiring treatment with vasopressors (dopamine \> 5 mg / kg / min or any dose of epinephrine, norepinephrine, phenylephrine, or vasopressin) for at least 2 hours to maintain systolic blood pressure (sbp) \> 90 mmhg (or mean blood pressure \[mbp\] \> 70 mmhg) after adequate fluid administration. 5. patients who are not expected to live more than 3 months due to other medical illnesses, such as neoplasia or other terminal illnesses. 6. patients with primary or metastatic lung cancer or with chemotherapy scheduled for the next 90 days. 7. patients with a known primary immunodeficiency disorder or with acquired immunodeficiency syndrome (hiv infection) with a cd4 count \<200 cells / mm3 or who do not have an undetectable viral load (\<200 copies). 8. patients receiving immunosuppressive therapy (including chronic treatment with any alpha antitumor necrosis factor \[tnfa\]) or corticosteroid therapy. 9. granulocytopenia, not due to sepsis, evidenced by an absolute neutrophil count \<500 per μl. 10. hematologic or lympho-reticular malignancies, unless in remission. 11. patients who have received a stem cell, organ, or bone marrow transplant in the last 6 months. 12. patients in current treatment with a biological product (eg, antibodies, cell therapy) or with plasmapheresis in the last 8 weeks. 13. patients who are currently receiving or have received another investigational drug in the 90 days prior to study initiation (or 5 halflives of the investigational compound, whichever is longer). 14. known allergies or hypersensitivity to antibiotics and/or any component of the investigational product. 15. patients with known severe liver function impairment. 16. patients with known severe kidney function impairment. 17. patients admitted in the previous 15 days for causes other than sars-cov-2 virus infection. 18. diseases other than sars-cov-2 virus infection leading to new york heart association class iv status. 19. terminal neuromuscular disorders that alter the gradual withdrawal of the ventilator (eg, amyotrophic lateral sclerosis). 20. patients with complete tetraplegia (traumatic or otherwise). 21. dementia-alzheimer and another situation in which is considered patient can not understand what is explaining, can not read or does not understand the language.

1. clinical diagnosis of critically serious lung involvement associated with sars-cov-2 virus infection according to the criteria of the national health commission of china, that is, patients who meet any of the following criteria: 1. respiratory failure requiring invasive mechanical ventilation; or 2. shock; or 3. combination with failure of another organ; need for icu admission for monitoring / treatment. 2. patients who are expected to develop rapidly fatal disease within 72 hours of enrollment. 3. inability to maintain a mean arterial pressure \> 50 mmhg before selection despite the presence of vasopressors and intravenous fluids. 4. patients requiring treatment with vasopressors (dopamine \> 5 mg / kg / min or any dose of epinephrine, norepinephrine, phenylephrine, or vasopressin) for at least 2 hours to maintain systolic blood pressure (sbp) \> 90 mmhg (or mean blood pressure \[mbp\] \> 70 mmhg) after adequate fluid administration. 5. patients who are not expected to live more than 3 months due to other medical illnesses, such as neoplasia or other terminal illnesses. 6. patients with primary or metastatic lung cancer or with chemotherapy scheduled for the next 90 days. 7. patients with a known primary immunodeficiency disorder or with acquired immunodeficiency syndrome (hiv infection) with a cd4 count \<200 cells / mm3 or who do not have an undetectable viral load (\<200 copies). 8. patients receiving immunosuppressive therapy (including chronic treatment with any alpha antitumor necrosis factor \[tnfa\]) or corticosteroid therapy. 9. granulocytopenia, not due to sepsis, evidenced by an absolute neutrophil count \<500 per μl. 10. hematologic or lympho-reticular malignancies, unless in remission. 11. patients who have received a stem cell, organ, or bone marrow transplant in the last 6 months. 12. patients in current treatment with a biological product (eg, antibodies, cell therapy) or with plasmapheresis in the last 8 weeks. 13. patients who are currently receiving or have received another investigational drug in the 90 days prior to study initiation (or 5 halflives of the investigational compound, whichever is longer). 14. known allergies or hypersensitivity to antibiotics and/or any component of the investigational product. 15. patients with known severe liver function impairment. 16. patients with known severe kidney function impairment. 17. patients admitted in the previous 15 days for causes other than sars-cov-2 virus infection. 18. diseases other than sars-cov-2 virus infection leading to new york heart association class iv status. 19. terminal neuromuscular disorders that alter the gradual withdrawal of the ventilator (eg, amyotrophic lateral sclerosis). 20. patients with complete tetraplegia (traumatic or otherwise). 21. dementia-alzheimer and another situation in which is considered patient can not understand what is explaining, can not read or does not understand the language.

clinical diagnosis of critically serious lung involvement associated with sars-cov-2 virus infection according to the criteria of the national health commission of china, that is, patients who meet any of the following criteria: respiratory failure requiring invasive mechanical ventilation; or shock; or combination with failure of another organ; need for icu admission for monitoring / treatment. patients who are expected to develop rapidly fatal disease within 72 hours of enrollment. inability to maintain a mean arterial pressure > 50 mmhg before selection despite the presence of vasopressors and intravenous fluids. patients requiring treatment with vasopressors (dopamine > 5 mg / kg / min or any dose of epinephrine, norepinephrine, phenylephrine, or vasopressin) for at least 2 hours to maintain systolic blood pressure (sbp) > 90 mmhg (or mean blood pressure [mbp] > 70 mmhg) after adequate fluid administration. patients who are not expected to live more than 3 months due to other medical illnesses, such as neoplasia or other terminal illnesses. patients with primary or metastatic lung cancer or with chemotherapy scheduled for the next 90 days. patients with a known primary immunodeficiency disorder or with acquired immunodeficiency syndrome (hiv infection) with a cd4 count <200 cells / mm3 or who do not have an undetectable viral load (<200 copies). patients receiving immunosuppressive therapy (including chronic treatment with any alpha antitumor necrosis factor [tnfa]) or corticosteroid therapy. granulocytopenia, not due to sepsis, evidenced by an absolute neutrophil count <500 per μl. hematologic or lympho-reticular malignancies, unless in remission. patients who have received a stem cell, organ, or bone marrow transplant in the last 6 months. patients in current treatment with a biological product (eg, antibodies, cell therapy) or with plasmapheresis in the last 8 weeks. patients who are currently receiving or have received another investigational drug in the 90 days prior to study initiation (or 5 halflives of the investigational compound, whichever is longer). known allergies or hypersensitivity to antibiotics and/or any component of the investigational product. patients with known severe liver function impairment. patients with known severe kidney function impairment. patients admitted in the previous 15 days for causes other than sars-cov-2 virus infection. diseases other than sars-cov-2 virus infection leading to new york heart association class iv status. terminal neuromuscular disorders that alter the gradual withdrawal of the ventilator (eg, amyotrophic lateral sclerosis). patients with complete tetraplegia (traumatic or otherwise). dementia-alzheimer and another situation in which is considered patient can not understand what is explaining, can not read or does not understand the language.

clinical diagnosis of critically serious lung involvement associated with sars-cov-2 virus infection according to the criteria of the national health commission of china, that is, patients who meet any of the following criteria: respiratory failure requiring invasive mechanical ventilation; or shock; or combination with failure of another organ; need for icu admission for monitoring / treatment. patients who are expected to develop rapidly fatal disease within 72 hours of enrollment. inability to maintain a mean arterial pressure > 50 mmhg before selection despite the presence of vasopressors and intravenous fluids. patients requiring treatment with vasopressors (dopamine > 5 mg / kg / min or any dose of epinephrine, norepinephrine, phenylephrine, or vasopressin) for at least 2 hours to maintain systolic blood pressure (sbp) > 90 mmhg (or mean blood pressure [mbp] > 70 mmhg) after adequate fluid administration. patients who are not expected to live more than 3 months due to other medical illnesses, such as neoplasia or other terminal illnesses. patients with primary or metastatic lung cancer or with chemotherapy scheduled for the next 90 days. patients with a known primary immunodeficiency disorder or with acquired immunodeficiency syndrome (hiv infection) with a cd4 count <200 cells / mm3 or who do not have an undetectable viral load (<200 copies). patients receiving immunosuppressive therapy (including chronic treatment with any alpha antitumor necrosis factor [tnfa]) or corticosteroid therapy. granulocytopenia, not due to sepsis, evidenced by an absolute neutrophil count <500 per μl. hematologic or lympho-reticular malignancies, unless in remission. patients who have received a stem cell, organ, or bone marrow transplant in the last 6 months. patients in current treatment with a biological product (eg, antibodies, cell therapy) or with plasmapheresis in the last 8 weeks. patients who are currently receiving or have received another investigational drug in the 90 days prior to study initiation (or 5 halflives of the investigational compound, whichever is longer). known allergies or hypersensitivity to antibiotics and/or any component of the investigational product. patients with known severe liver function impairment. patients with known severe kidney function impairment. patients admitted in the previous 15 days for causes other than sars-cov-2 virus infection. diseases other than sars-cov-2 virus infection leading to new york heart association class iv status. terminal neuromuscular disorders that alter the gradual withdrawal of the ventilator (eg, amyotrophic lateral sclerosis). patients with complete tetraplegia (traumatic or otherwise). dementia-alzheimer and another situation in which is considered patient can not understand what is explaining, can not read or does not understand the language.

1. clinical diagnosis of critically serious lung involvement associated with sars-cov-2 virus infection according to the criteria of the national health commission of china, that is, patients who meet any of the following criteria: 1. respiratory failure requiring invasive mechanical ventilation; or 2. shock; or 3. combination with failure of another organ; need for icu admission for monitoring / treatment. 2. patients who are expected to develop rapidly fatal disease within 72 hours of enrollment. 3. inability to maintain a mean arterial pressure > 50 mmhg before selection despite the presence of vasopressors and intravenous fluids. 4. patients requiring treatment with vasopressors (dopamine > 5 mg / kg / min or any dose of epinephrine, norepinephrine, phenylephrine, or vasopressin) for at least 2 hours to maintain systolic blood pressure (sbp) > 90 mmhg (or mean blood pressure [mbp] > 70 mmhg) after adequate fluid administration. 5. patients who are not expected to live more than 3 months due to other medical illnesses, such as neoplasia or other terminal illnesses. 6. patients with primary or metastatic lung cancer or with chemotherapy scheduled for the next 90 days. 7. patients with a known primary immunodeficiency disorder or with acquired immunodeficiency syndrome (hiv infection) with a cd4 count <200 cells / mm3 or who do not have an undetectable viral load (<200 copies). 8. patients receiving immunosuppressive therapy (including chronic treatment with any alpha antitumor necrosis factor [tnfa]) or corticosteroid therapy. 9. granulocytopenia, not due to sepsis, evidenced by an absolute neutrophil count <500 per μl. 10. hematologic or lympho-reticular malignancies, unless in remission. 11. patients who have received a stem cell, organ, or bone marrow transplant in the last 6 months. 12. patients in current treatment with a biological product (eg, antibodies, cell therapy) or with plasmapheresis in the last 8 weeks. 13. patients who are currently receiving or have received another investigational drug in the 90 days prior to study initiation (or 5 halflives of the investigational compound, whichever is longer). 14. known allergies or hypersensitivity to antibiotics and/or any component of the investigational product. 15. patients with known severe liver function impairment. 16. patients with known severe kidney function impairment. 17. patients admitted in the previous 15 days for causes other than sars-cov-2 virus infection. 18. diseases other than sars-cov-2 virus infection leading to new york heart association class iv status. 19. terminal neuromuscular disorders that alter the gradual withdrawal of the ventilator (eg, amyotrophic lateral sclerosis). 20. patients with complete tetraplegia (traumatic or otherwise). 21. dementia-alzheimer and another situation in which is considered patient can not understand what is explaining, can not read or does not understand the language.

1. clinical diagnosis of critically serious lung involvement associated with sars-cov-2 virus infection according to the criteria of the national health commission of china, that is, patients who meet any of the following criteria: 1. respiratory failure requiring invasive mechanical ventilation; or 2. shock; or 3. combination with failure of another organ; need for icu admission for monitoring / treatment. 2. patients who are expected to develop rapidly fatal disease within 72 hours of enrollment. 3. inability to maintain a mean arterial pressure > 50 mmhg before selection despite the presence of vasopressors and intravenous fluids. 4. patients requiring treatment with vasopressors (dopamine > 5 mg / kg / min or any dose of epinephrine, norepinephrine, phenylephrine, or vasopressin) for at least 2 hours to maintain systolic blood pressure (sbp) > 90 mmhg (or mean blood pressure [mbp] > 70 mmhg) after adequate fluid administration. 5. patients who are not expected to live more than 3 months due to other medical illnesses, such as neoplasia or other terminal illnesses. 6. patients with primary or metastatic lung cancer or with chemotherapy scheduled for the next 90 days. 7. patients with a known primary immunodeficiency disorder or with acquired immunodeficiency syndrome (hiv infection) with a cd4 count <200 cells / mm3 or who do not have an undetectable viral load (<200 copies). 8. patients receiving immunosuppressive therapy (including chronic treatment with any alpha antitumor necrosis factor [tnfa]) or corticosteroid therapy. 9. granulocytopenia, not due to sepsis, evidenced by an absolute neutrophil count <500 per μl. 10. hematologic or lympho-reticular malignancies, unless in remission. 11. patients who have received a stem cell, organ, or bone marrow transplant in the last 6 months. 12. patients in current treatment with a biological product (eg, antibodies, cell therapy) or with plasmapheresis in the last 8 weeks. 13. patients who are currently receiving or have received another investigational drug in the 90 days prior to study initiation (or 5 halflives of the investigational compound, whichever is longer). 14. known allergies or hypersensitivity to antibiotics and/or any component of the investigational product. 15. patients with known severe liver function impairment. 16. patients with known severe kidney function impairment. 17. patients admitted in the previous 15 days for causes other than sars-cov-2 virus infection. 18. diseases other than sars-cov-2 virus infection leading to new york heart association class iv status. 19. terminal neuromuscular disorders that alter the gradual withdrawal of the ventilator (eg, amyotrophic lateral sclerosis). 20. patients with complete tetraplegia (traumatic or otherwise). 21. dementia-alzheimer and another situation in which is considered patient can not understand what is explaining, can not read or does not understand the language.